RMI 10874
目录号 : GC32368
RMI10874是一种Tilorone类似物。Tilorone是一种小分子口服有效的抗病毒剂。RMI10874完全消除H-2阴性(GR9.B9)MCA诱导的纤维肉瘤的肺孢子菌定植。
Cas No.:38020-45-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
RMI 10874 is a tilorone analogue. Tilorone is a small-molecule, orally bioavailable antiviral agent. RMI 10874 completely abolishes lung colonization of an H-2 negative (GR9.B9) MCA-induced fibrosarcoma clone.
The effect of RMI 10874 (RMI 10,874DA) in the abrogation of the metastatic spread of tumor cells is studied. Pre-treatment of BALB/c mice with the RMI 10,874DA completely eliminates lung colonization of an H-2-negative (GR9.B9) MCA-induced fibrosarcoma clone in an experimental metastasis assay[1]. The effect of a tilorone analogue (RMI 10,874DA) and anti-asialo GM1 serum is studied on the survival of BALB/c and C57B1/6 mice after i.v. injections of different syngeneic murine tumor cells. Natural killer (NK) cell activation in vivo by RMI 10874 prolongs survival and inhibits metastasis formation in mice, even when pretreatment consists of a single dose of the analogue[2]. Tilorone is a small-molecule, orally bioavailable drug that is used clinically as an antiviral[3].
[1]. Algarra I, et al. Generation and control of metastasis in experimental tumor systems; inhibition of experimental metastases by a tilorone analogue. Int J Cancer. 1993 May 28;54(3):518-23. [2]. Algarra I, et al. Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Clin Exp Immunol. 1996 Mar;103(3):499-505. [3]. Ekins S, et al. Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection. Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01711-17.
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6995 mL | 13.4975 mL | 26.9949 mL |
| 5 mM | 0.5399 mL | 2.6995 mL | 5.399 mL |
| 10 mM | 0.2699 mL | 1.3497 mL | 2.6995 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。